01.02.2010 • News

Siegfried to Introduce Functional Organization

Siegfried has announced its intention to replace its current two-division structure with a functional organization effective from March 1. The company said it will increasingly market its two core capabilities - the development and production of active pharmaceutical ingredients and finished dosage forms - as a single package.

"Siegfried ... is capable of providing both the chemical synthesis of active pharmaceutical ingredients and production of finished dosage forms," CEO Rudolf Hanko said. "Our new organizational structure will make allowance for this fact."

Executive Committee Changes
The future executive committee of Siegfried will consist of seven members: Rudolf Hanko, CEO; Michael Hüsler, CFO; and Hanspeter Brun, Head of HR; will continue in the same function. Marianne Späne, formerly head of the Siegfried Generics division, will be responsible for Business Development and Sales. Hubert Stückler, formerly head of the Siegfried Actives division, will be responsible for the worldwide technical operations. Former chief communications officer, Peter Gehler, will head the Corporate Center, which includes communication, the legal department, facility management and the chairman's
office. In addition to his duties as CEO, Rudolf Hanko will assume responsibility for Research
& Development on an interim basis until the position of head of R&D is filled.

 

Company

Logo:

Siegfried

Untere Brühlstr. 4
4800 Zofingen
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.